Home > Resources > Whitepapers > White Paper on Personalised Medicine

White Paper on Personalised Medicine

The White Paper describes the challenges in delivering personalised medicine, from the classification of disease, the need for greater investment in e-health and big data infrastructure, to calls for effective regulatory science and access mechanisms for the benefit of patients. We, at EBE, believe it is a top priority to establish data privacy and protection laws which effectively protect patients while at the same time making pan-European research initiatives possible. Likewise, appropriate regulation needs to ensure access to reliable methods for correct diagnosis.

I'm For Real

Enter your details once to access all our information and resources

Spotlight

BenevolentAI

BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, having discovered a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.

OTHER WHITEPAPERS
news image

Using Clinical Breakpoints to Improve Antimicrobial Resistance Detection

whitePaper | December 13, 2022

Define the ongoing pandemic of antimicrobial resistance. Discuss how we can address the ongoing pandemicin the Clinical Microbiology Laboratory

Read More
news image

Making the Promise of mRNA a Reality: OvercomingScale-Up Challenges

whitePaper | March 22, 2023

If scaling issues strike you as obvious or even boring, you should read “On Being the Right Size,” a 1926 essay by geneticist J.B.S. Haldane. It makes the case that a difference in scale—a seemingly simple matter—may demand subtle changes in form and function.

Read More
news image

Viral Vectors as a Gene Delivery Vehicle

whitePaper | August 5, 2022

The field of gene and cell therapy is experiencing a renaissance, with innovations in the use of viral vectors as a gene delivery vehicle being a key factor in the field’s growth.

Read More
news image

Multi-Attribute Methods for Biopharmaceutical Analysis

whitePaper | December 5, 2022

The adoption of LC-MS-based multi-attribute method (MAM) analysis for routine monitoring of biotherapeutic variation has progressed greatly over the last five years.

Read More
news image

U.S. Biopharma Expansions to Europe: Ensuring Successful Build-Out & Market Access

whitePaper | May 24, 2023

The Greater Zurich Area Ltd (GZA), Apellis, and Korn Ferry co-hosted a virtual roundtable for a select group of biopharma leaders interested in expanding their operations into Europe. The panel brought together European launch specialists, talent experts, and Swiss government officials to cover critical questions and guiding principles necessary for a successful European launch, as well as insider knowledge of how to best navigate the regulatory environment.

Read More
news image

Transforming cell & gene therapy manufacturing

whitePaper | February 25, 2022

Digitalization and automation promise a better way to streamline the transfer of cell and gene therapies from drug discovery – to commercial production.

Read More

Using Clinical Breakpoints to Improve Antimicrobial Resistance Detection

whitePaper | December 13, 2022

Define the ongoing pandemic of antimicrobial resistance. Discuss how we can address the ongoing pandemicin the Clinical Microbiology Laboratory

Read More

Making the Promise of mRNA a Reality: OvercomingScale-Up Challenges

whitePaper | March 22, 2023

If scaling issues strike you as obvious or even boring, you should read “On Being the Right Size,” a 1926 essay by geneticist J.B.S. Haldane. It makes the case that a difference in scale—a seemingly simple matter—may demand subtle changes in form and function.

Read More

Viral Vectors as a Gene Delivery Vehicle

whitePaper | August 5, 2022

The field of gene and cell therapy is experiencing a renaissance, with innovations in the use of viral vectors as a gene delivery vehicle being a key factor in the field’s growth.

Read More

Multi-Attribute Methods for Biopharmaceutical Analysis

whitePaper | December 5, 2022

The adoption of LC-MS-based multi-attribute method (MAM) analysis for routine monitoring of biotherapeutic variation has progressed greatly over the last five years.

Read More

U.S. Biopharma Expansions to Europe: Ensuring Successful Build-Out & Market Access

whitePaper | May 24, 2023

The Greater Zurich Area Ltd (GZA), Apellis, and Korn Ferry co-hosted a virtual roundtable for a select group of biopharma leaders interested in expanding their operations into Europe. The panel brought together European launch specialists, talent experts, and Swiss government officials to cover critical questions and guiding principles necessary for a successful European launch, as well as insider knowledge of how to best navigate the regulatory environment.

Read More

Transforming cell & gene therapy manufacturing

whitePaper | February 25, 2022

Digitalization and automation promise a better way to
streamline the transfer of cell and gene therapies from
drug discovery – to commercial production.

Read More
More Whitepapers

Spotlight

BenevolentAI

BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, having discovered a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.

Events

8th International Conference on Bio-Sensing Technology

Conference